10 unknown, 6 completed, 5 not yet recruiting, 5 recruiting. 30 Phase 1, 25 Phase 2.
Follow Chidamide: new trials by email Literature Review of Chidamide trials Research Report on Chidamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma Lisaftoclax, Chidamide, rituximab - Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 51 | 2026-05-30 | 2026-05-22 |
| Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy Chidamide, radiotherapy - Head and Neck Squamous Cell Carcinoma HNSCC | Phase 1 | Recruiting | West China Hospital | 6 | 2026-04-23 | 2026-04-28 |
| Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL Polatuzumab Vedotin, Rituximab (R), Chidamide - Double Expressor DLBCL | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 68 | 2026-04-01 | 2026-02-17 |
| Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. Chidamide, Toripalimab, Anlotinib - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 52 | 2026-03-31 | 2026-03-20 |
| EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas Zeprumetostat, Golidocitinib, Chidamide - Mature T-cell and NK-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 60 | 2026-01-01 | 2026-01-14 |
| Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Linperlisib, Chidamide - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 54 | 2025-09-15 | 2025-08-24 |
| Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma Golidocitinib, Mitoxantrone Hydrochloride Liposome, Chidamide - Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 101 | 2025-08-27 | 2025-12-31 |
| Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma golidocitinib, Chidamide - Cutaneous T-cell Lymphoma (CTCL) | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 65 | 2025-08-26 | 2026-08-12 |
| A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 42 | 2023-10-30 | 2023-11-02 |
| Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC) Chidamide, Regorafenib - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Great Novel Therapeutics Biotech & Medicals Corporation | 7 | 2023-04-25 | 2025-03-11 |
| Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT Chidamide - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Recruiting | Sichuan University | 77 | 2022-12-22 | 2023-01-12 |
| Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer Chidamide - Breast Cancer, Chemotherapy Effect | Phase 1 / Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2022-11-01 | 2023-02-28 |
| Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study Dalpiciclib, Chidamide - HR+/HER2- Advanced Breast Cancer | Phase 1 | Completed | Beijing 302 Hospital | 22 | 2022-10-01 | 2026-05-29 |
| Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) chidamide, celecoxib - Metastatic Colorectal Cancer | Phase 1 | Terminated | Taipei Medical University Shuang Ho Hospital | 9 | 2022-09-20 | 2024-12-20 |
| Chidamide in Combination With Abemaciclib and Endocrinotherapy(Doctor's Choice) in Breast Cancer Patients Previously Treated With Palbociclib Chidamide, Abemaciclib, endocrinotherapy(doctor's choice) - Breast Cancer | Phase 1 / Phase 2 | Unknown | Biyun Wang, MD | 44 | 2022-07-01 | 2024-01-22 |
| APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma APG-1252, Chidamide - NHL, Adult | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 51 | 2022-06-14 | 2024-01-23 |
| Chidamide Bridging for CAR-T Therapy Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells - Non Hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 120 | 2022-05-25 | 2024-03-06 |
| Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors Chidamide, Decitabine, Immune checkpoint inhibitors(anti-PD1/PD-L1/CTLA4 antibodies) - Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2022-03-30 | 2022-04-11 |
| PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Parsaclisib, Chidamide - Peripheral T-Cell Lymphoma | Phase 1 | Terminated | Henan Cancer Hospital | 12 | 2022-02-20 | 2025-12-02 |
| Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse Azacitidine, Chidamide - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 40 | 2022-02-01 | 2026-07-07 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, Non-Hodgkin (5) · Lymphoma, T-Cell, Peripheral (3) · Breast Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, T-Cell (2) · Recurrence (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Nasopharyngeal Carcinoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Thrombocytopenia (1)
Sun Yat-sen University (6) · Chinese PLA General Hospital (4) · Chipscreen Biosciences, Ltd. (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Peking Union Medical College Hospital (2) · Ascentage Pharma Group Inc. (1) · Beijing 302 Hospital (1) · Biyun Wang, MD (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Great Novel Therapeutics Biotech & Medicals Corporation (1) · Henan Cancer Hospital (1) · Huiqiang Huang (1) · Shandong University (1) · Sichuan University (1) · Taipei Medical University Shuang Ho Hospital (1)
China (23) · Taiwan (2)
Binghe Xu (1) · Biyun Wang (1) · Chia-Nan Chen, Ph.D. (1) · Daobin Zhou, M.D (1) · Jianxiang Wang, Dr (1) · Rui Huang, Doctor (1) · Weidong Han, M.D. (1) · Weidong Han, Ph.D (1) · Weidong Han, Prfessor (1) · Xingchen Peng (1) · Yanyan Liu, M.D. Ph.D (1) · Yifan Zhai, MD, PhD (1) · Yongtao Sun, M.D., Ph.D. (1) · Yuankai Shi, MD (1)